Optimal reference interval for homeostasis model assessment of insulin resistance in a Japanese population

Journal of Diabetes Investigation

Volumn 2, Issue 5, 2011, Pages 373-376

  Yamada, Chizumi ^a   Mitsuhashi, Toshitake ^a   Hiratsuka, Noboru ^a   Inabe, Fumiyo ^a   Araida, Nami ^a   Takahashi, Eiko ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

C28 A3; Homeostasis model assessment of insulin resistance; Reference interval

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYTIC METHOD; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HUMAN EXPERIMENT; INSULIN RESISTANCE; JAPANESE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VALIDITY;

EID: 80053940853     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00113.x     Document Type: Article

References (19)

1. Clinical and Laboratory Standards Institute (CLSI). Defining, Establishing, and Verifying Reference Intervals in the Clinical laboratory; Approved Guideline - Third Edition CLSI document C28-A3 (ISBN 1-56238-682-4), 2008.
2. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
3. Alberti KG, Eckel RH, Grundy SM, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
4. Eckel RH, Alberti KG, Grundy SM, et al. The metabolic syndrome. Lancet 2010; 375: 181-183.
5. WHO. Physical Status: The Use and Interpretation of Anthropometry. Report of a WHO Expert Consultation. WHO Technical Report Series Number 854. World Health Organization, Geneva, 1995.
6. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-163.
7. Schindhelm RK, Diamant M, Dekker JM, et al. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006; 22: 437-443.
8. Japan Diabetes Society. Treatment Guide for Diabetes 2010. Treatment Guide for Diabetes Editorial Committee (eds). Bunkodo, Tokyo, 2010 (Japanese).
9. Taniguchi A, Fukushima M, Sakai M, et al. Remnant-like particle cholesterol, triglycerides, and insulin resistance in nonobese Japanese type 2 diabetic patients. Diabetes Care 2000; 23: 1766-1769.
10. Chang SA, Kim HS, Yoon KH, et al. Body mass index is the most important determining factor for the degree of insulin resistance in non-obese type 2 diabetic patients in Korea. Metabolism 2004; 53: 142-146.
11. Masuo K, Katsuya T, Ogihara T, et al. Acute hyperinsulinemia reduces plasma leptin levels in insulin-sensitive Japanese men. Am J Hypertens 2005; 18: 235-243.
12. Yoshitomi Y, Ishii T, Kaneki M, et al. Relationship between insulin resistance and effect of atorvastatin in non-diabetic subjects. J Atheroscler Thromb 2005; 12: 9-13.
13. Nakai Y, Nakaishi S, Kishimoto H, et al. The threshold value for insulin resistance on homeostasis model assessment of insulin sensitivity. Diabet Med 2002; 19: 346-347.
14. Ohnishi H, Saitoh S, Takagi S, et al. Incidence of insulin resistance in obese subjects in a rural Japanese population: the Tanno and Sobetsu study. Diabetes Obes Metab 2004; 7: 83-87.
15. Matsumoto K, Miyake S, Yano M, et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care 1997; 20: 1562-1568.
16. Shimomura H, Maehata E, Kawaguchi T, et al. Trial setting of the insulin resistance index homeostasis model assessment ratio: HOMA-R reference values for targeting recipients of medical examinations. Seitai Siryo Bunseki 2003; 26: 123-128 (Japanese).
17. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998; 47: 1643-1649.
18. Ascaso JF, Romero P, Real JT, et al. Insulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population. Med Clin (Barc) 2001; 117: 530-533 (Spanish).
19. Lee JM, Okumura MJ, Davis MM, et al. Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study. Diabetes Care 2006; 29: 2427-2432.